Masimo Corporation $MASI Shares Acquired by Bellevue Group AG

Bellevue Group AG lifted its stake in shares of Masimo Corporation (NASDAQ:MASI) by 28.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 89,673 shares of the medical equipment provider’s stock after purchasing an additional 19,865 shares during the period. Bellevue Group AG’s holdings in Masimo were worth $15,085,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bamco Inc. NY raised its stake in Masimo by 21.2% during the second quarter. Bamco Inc. NY now owns 384,589 shares of the medical equipment provider’s stock valued at $64,696,000 after buying an additional 67,307 shares in the last quarter. 4D Advisors LLC grew its position in shares of Masimo by 50.0% in the 2nd quarter. 4D Advisors LLC now owns 45,000 shares of the medical equipment provider’s stock worth $7,570,000 after acquiring an additional 15,000 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Masimo by 517.2% in the 2nd quarter. AQR Capital Management LLC now owns 50,256 shares of the medical equipment provider’s stock worth $8,454,000 after acquiring an additional 42,114 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Masimo by 86.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 394,487 shares of the medical equipment provider’s stock valued at $66,361,000 after acquiring an additional 182,701 shares during the last quarter. Finally, Alamea Verwaltungs GmbH raised its position in shares of Masimo by 30.7% during the 2nd quarter. Alamea Verwaltungs GmbH now owns 2,566 shares of the medical equipment provider’s stock valued at $432,000 after acquiring an additional 603 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on MASI. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Bank of America began coverage on shares of Masimo in a report on Monday, November 17th. They issued a “neutral” rating and a $162.00 price target for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Finally, BTIG Research increased their price objective on shares of Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Masimo currently has a consensus rating of “Hold” and a consensus price target of $189.40.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $138.34 on Friday. Masimo Corporation has a 12-month low of $133.70 and a 12-month high of $194.88. The company has a market cap of $7.43 billion, a PE ratio of -13.13, a P/E/G ratio of 1.53 and a beta of 1.26. The stock has a 50 day simple moving average of $145.31 and a 200-day simple moving average of $151.48. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69.

Masimo (NASDAQ:MASI) last announced its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.The firm had revenue of $617.00 million for the quarter. On average, equities research analysts forecast that Masimo Corporation will post 4.1 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.